Best Nanotechnology Stocks To Watch Now – February 21st

OSI Systems, NVE, Virpax Pharmaceuticals, Clene, and Biodexa Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks refer to shares or securities of companies specializing in the development, research, and application of nanotechnology – the manipulation of matter at an atomic or molecular scale. Investors purchase these stocks to potentially profit from advancements and commercialization in the field of nanotechnology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ:OSIS traded down $13.40 during mid-day trading on Friday, reaching $200.97. The stock had a trading volume of 94,053 shares, compared to its average volume of 210,027. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. The company has a market cap of $3.38 billion, a P/E ratio of 25.94, a price-to-earnings-growth ratio of 1.85 and a beta of 1.19. OSI Systems has a 1 year low of $126.57 and a 1 year high of $220.00. The business’s 50 day moving average price is $183.86 and its 200 day moving average price is $161.79.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NASDAQ NVEC traded down $2.31 during trading hours on Friday, reaching $73.98. The stock had a trading volume of 6,646 shares, compared to its average volume of 25,662. The business’s fifty day moving average price is $77.42 and its two-hundred day moving average price is $78.19. The firm has a market cap of $358.04 million, a price-to-earnings ratio of 23.86 and a beta of 1.11. NVE has a 52-week low of $67.35 and a 52-week high of $90.24.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of VRPX traded down $0.02 during mid-day trading on Friday, reaching $0.27. The company had a trading volume of 1,058,507 shares, compared to its average volume of 5,319,184. The stock has a 50 day moving average of $0.33 and a two-hundred day moving average of $0.56. Virpax Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $5.48.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of NASDAQ:CLNN traded down $0.06 during trading on Friday, hitting $4.46. 43,623 shares of the stock traded hands, compared to its average volume of 59,351. The company has a market cap of $37.11 million, a price-to-earnings ratio of -0.84 and a beta of 0.24. The company has a fifty day moving average price of $4.83 and a two-hundred day moving average price of $5.06. Clene has a 52-week low of $3.82 and a 52-week high of $10.40.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

BDRX traded down $0.08 on Friday, hitting $3.72. 28,389 shares of the company’s stock were exchanged, compared to its average volume of 736,418. The firm’s 50-day simple moving average is $4.30. Biodexa Pharmaceuticals has a fifty-two week low of $3.36 and a fifty-two week high of $74.00.